Topics

Tocagen plummets on phase 3 data for glioma therapy

05:33 EDT 13 Sep 2019 | pharmaphorum

A phase 3 trial of Tocagen’s therapy for high-grade glioma (HGG) – a form of brain cancer – failed to show an improvement in overall survival, sending the biotech’s shares into freefall. The Toca 5 study of Toca 511 and Toca FC showed that patient...

Original Article: Tocagen plummets on phase 3 data for glioma therapy

NEXT ARTICLE

More From BioPortfolio on "Tocagen plummets on phase 3 data for glioma therapy"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...